NASDAQ · DMACHealthcarePharmaceuticals

DiaMedica Therapeutics news

$8.20−1.44%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About DiaMedica Therapeutics

No recent articles focused on DiaMedica Therapeutics.

Also mentions DMAC

Articles that tag DMAC but are mainly about other companies.

Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight

GlobeNewswire Inc.Mar 2, 1:00 PM ET▲ Positive

DM199 is in pivotal Phase III ReMEDy2 trial with first patient dosed in April 2024 and interim analysis planned for Q2 2026, indicating active development progress.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology